BriaCell and BeiGene Agree on Bria-OTS™ Clinical Supply for First Human Study

BriaCell Therapeutics, a clinical-stage biotechnology firm specializing in innovative cancer immunotherapies, has entered into a strategic clinical supply agreement with BeiGene. This collaboration aims to assess the safety and efficacy of BriaCell’s next-generation immunotherapy, Bria-OTS™, combined with BeiGene’s anti-PD-1 antibody, tislelizumab, for the treatment of advanced, heavily pretreated metastatic breast cancer.

Dr. William V. Williams, BriaCell’s President and CEO, expressed enthusiasm about the partnership, noting it as a significant milestone in their mission to revolutionize cancer treatment. He highlighted plans for potential expansion of this novel immunotherapy approach to other forms of cancer, including prostate cancer.

Dr. Del Priore, BriaCell’s Chief Medical Officer, emphasized that the Bria-OTS™ platform builds upon the success of Bria-IMT™, which has demonstrated clinical benefits even after resistance to checkpoint inhibitors (CPIs). In various trials, including a randomized Phase 2 study, Bria-IMT™ showed survival benefits and clinical improvements in patients with central nervous system (CNS) metastases and those who had progressed following treatment with antibody-drug conjugates (ADCs). The new Bria-OTS™ platform represents an advanced off-the-shelf therapy with enhanced potency, and there is a sound rationale to anticipate that combining Bria-OTS™ with tislelizumab could offer additional benefits for patients who have exhausted other treatment options.

The initial phase of the limited-access Phase 1/2 clinical trial will focus on evaluating the safety and efficacy of Bria-OTS™ as a monotherapy for breast cancer. Subsequent phases will explore the effects of the combined treatment with tislelizumab. Beyond breast cancer, BriaCell intends to extend the evaluation of Bria-OTS™ to prostate cancer and other malignancies.

BriaCell Therapeutics continues to make strides in developing breakthrough immunotherapies aimed at transforming the current landscape of cancer care.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!